临床试验/NCT07172477

NCT07172477招募中不适用

Early Feasibility Study (EFS) of the 'Pivot Extend' for the Treatment of Tricuspid Regurgitation, Including High-Risk Patients (SPACER Study, Australia)

Tau Medical Australia Pty Ltd2 个研究点分布在 1 个国家目标入组 10 人开始时间: 2025年11月11日最近更新: 2025年12月9日

适应症

试验速览

阶段: 不适用
状态: 招募中
发起方
入组人数: 10
试验地点: 2
主要终点: To evaluate the safety of the implantation of the "Pivot Extend" device

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Participants with severe tricuspid regurgitation may require heart surgery to repair or replace the tricuspid valve. However, there is a high risk associated with these surgeries and it is often not feasible for elderly patients or those with other medical conditions.

The goal of this clinical investigation is

To assess the safety of the investigational device "Pivot Extend" in participants aged 18 years or over with severe and clinically symptomatic Tricuspid Regurgitation (TR) deemed suitable for percutaneous valve intervention
To evaluate device success, procedural success and clinical outcomes in improving TR symptoms following implantation of the "Pivot Extend" device

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Has voluntarily decided to participate in this clinical trial and has provided written informed consent
•Adults aged 18 years or older at the time of informed consent
•Has symptoms of TR corresponding to at least NYHA Class II, despite receiving optimal medical therapy for at least 30 days prior to screening
•Meets the criteria at least severe (3+) on the TR grade classification table on echocardiography performed at the screening visit
•Deemed suitable for percutaneous valve intervention by a Heart Team that includes at least one cardiologist and one cardiac surgeon
•Is able to understand and follow the investigator's instructions and is able to participate for the entire duration of the study

排除标准

•Has blood clots, emboli, masses, or growths in the vascular system of the heart or lungs on an echocardiogram and cardiac CT scan performed at the screening visit
•Uncorrected blood clotting disorders based on hematology tests performed at the screening visit
•Unable to use anticoagulant agents (NOAC ex.Xarelto)
•A history of major bleeding (excluding minor bleeding such as nosebleed that can be hemostasized) treated with anticoagulants at any time prior to participation in this clinical trial
•Severe anemia (hemoglobin less than or equal to 80g/L)
•Has an implanted device such as an implantable cardioverter defibrillator (ICD) or pacemaker
•Has anatomy that, in the opinion of the investigator, is not suitable for implantation of an investigational medical device based on echocardiogram and cardiac CT scan performed at the screening visit
•Requires surgery or interventional procedures (coronary artery bypass graft (CABG) or surgery for atrial septal defect (ASD)) based on an echocardiogram performed at the screening visit
•Platelet count of 50 x 10^9 per litre of blood or less based on hematology tests performed at the screening visit
•Pulmonary arterial hypertension, defined as pulmonary artery systolic pressure greater than 70mmHg on cardiac catheterization performed at the screening visit, or a pulmonary vascular resistance greater than 3 Wood Units on right heart catheterization
•Left ventricular ejection fraction (LVEF) of less than 20% on echocardiogram performed at the screening visit
•Active gastrointestinal bleeding or a digestive procedure within 90 days prior to screening for this study, and/or those with the potential for gastrointestinal bleeding in the opinion of the investigator
•History of cerebrovascular accident (CVA) or transient ischemic attacks (TIA) within 30 days prior to screening for this clinical trial
•History of myocardial infarction (MI) within 30 days prior to screening for this study
•Active endocarditis requiring antibiotic treatment
•Malignancies or end-stage renal failure requiring hemodialysis and other chronic conditions with a life expectancy of less than one year
•Moderate or severe aortic, pulmonary artery, or mitral stenosis on echocardiogram performed at the screening visit
•Severe or greater mitral valve regurgitation or severe aortic valve regurgitation as determined by echocardiographic grading criteria at the screening visit
•Calcification of the tricuspid valve leaflets affecting the procedure on an echocardiogram performed at the screening visit
•Those who have participated in another clinical trial within 30 days prior to screening for this clinical trial
•Pregnant or breastfeeding, or planning to become pregnant during the clinical trial period
•Participants of childbearing potential who are not using a highly effective method of contraception
•Coexisting condition, which most likely limits the life expectancy to less than one year
•Preexisting pulmonary valve prosthesis or a right ventricle to pulmonary artery (RV-PA) conduit
•Any other clinical findings that, in the opinion of the investigator, are medically inappropriate for this clinical trial

结局指标

主要结局

To evaluate the safety of the implantation of the "Pivot Extend" device

时间窗: 30 days post device implantation

Occurrence rate of major adverse cardiac events (MACE) (e.g. stroke, myocardial infarction, pulmonary embolism)

次要结局

To evaluate the Pivot Extend device success(During implantation procedure)
To evaluate the procedural success (1)(30 days, 180 days and 365 days post device implantation)
To evaluate the procedural success (3)(180 and 365 days after device implantation)
To evaluate the procedural success (2)(30 days, 180 days and 365 days post device implantation)
To evaluate the clinical outcomes (1)(180 days and 365 days post device implantation)
To evaluate the clinical outcomes (2)(180 days and 365 days post device implantation)
To evaluate the clinical outcomes (3)(30 days, 180 days and 365 days post device implantation)
To evaluate the procedural success (4)(30 days, 180 days and 365 days post device implantation)
To evaluate clinical outcomes (4)(30 days, 180 days and 365 days post device implantation)
To evaluate clinical outcomes (5)(30 days, 180 days and 365 days post device implantation)
To evaluate clinical outcomes (6)(30 days, 180 days and 365 days post device implantation)
To evaluate clinical outcome measures (7)(30 days, 180 days and 365 days post device implantation)

研究者

发起方

Tau Medical Australia Pty Ltd

申办方类型

Industry

责任方

Sponsor

研究点 (2)

Loading locations...

相似试验

进行中（未招募）

不适用

TRICuspid Intervention in Heart Failure TrialHeart Failure Attributable to Severe Tricuspid Regurgitation

NCT04634266LMU Klinikum360

已完成

不适用

The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve DiseaseTricuspid Valve Regurgitation

NCT01246141Xijing Hospital68

招募中

不适用

Feasibility Study of the DragonFly-T System for Severe Tricuspid RegurgitationTricuspid Regurgitation

NCT05671640Hangzhou Valgen Medtech Co., Ltd10

已完成

不适用

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTRFunctional Tricuspid Regurgitation

NCT05854095Tau Pnu Medical Co., Ltd.15

尚未招募

不适用

Concomitant Tricuspid Repair in Patients With Left Heart SurgeryCardiopulmonary BypassMitral RegurgitationTricuspid Regurgitation

NCT05595187Nanjing Medical University400